A new report from Future Market Insights reveals that global atopic
dermatitis treatment market revenue is set to expand at a CAGR of
12.8% over the forecast period (2017–2027). In recent years, the
prevalence of atopic dermatitis has increased to a great extent,
leading to higher demand for its treatment. In addition, the arrival
of novel drugs and therapeutic options is also facilitating the
growth of the global atopic dermatitis treatment market. Towards the
end of 2027, the market is expected to reach a valuation of US$
23,992.3 Mn. This growth will be further driven by continuous
research and drug development and the introduction of revised
reimbursement policies.
The report, titled “Atopic Dermatitis Treatment Market: Global
Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027”
has also analysed the market by splitting it into regional segments.
The dominance of North America on the global atopic dermatitis
treatment is expected to remain throughout the assessment period. In
2016, the region’s dermatitis treatment market accounted for a
revenue share of 30%. The market in the region is anticipated to
witness a CAGR of 16.0% to reach a valuation of US$ 10,384 Mn over
2027. Meanwhile, the market is Western Europe will maintain its
second position behind North America. Pharma companies in Europe are
concentrating on expanding their product portfolio by acquiring
smaller companies specialised in dermatology portfolios. The report
also projects a considerable growth of the atopic dermatitis
treatment market in Asia pacific excluding Japan (APEJ) over the next
couple of years.
By drug class, corticosteroids currently account for the largest
revenue share of the market. However, biologic therapy and PDE-4
inhibitor are expected to outsell corticosteroids by the end of
forecast period.
Biologic therapy is projected to account for around 36.4% share of
the market over 2027, expanding at a CAGR of 26.4%. During the same
period, the revenue share of PDE-4 inhibitor is expected to expand at
a staggering CAGR of 33.4%.
Request for Table of Contents @
In 2017 and beyond, preference for drug administration using topical
procedures will remains significantly high as compared to oral and
injectable administration modes. Topical drug administration will
account for more than two-third share of the market by 2027-end.
Hospital pharmacies remain the leading distribution channel despite
the rapid proliferation of dermatology clinics. In 2017, hospital
pharmacy will represent a market share of 33.1%, which will incur a
slight downtrend and settle for 31.4% by the end of 2027.
Some of the leading pharmaceutical companies that have an active
participation in the global atopic dermatitis treatment market
include: Sanofi SA, Galderma SA, Allergan Plc., Novartis,
Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma
Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Aqua
Pharmaceuticals (An Almirall Company), Pfizer, Dow Pharm, Connetics
Corporation, Fujisawa Healthcare, Encore Dermatology, LEO Pharma,
Velite Pharmaceutical, Biofrontera AG.
Many of these market players are implementing strategies such as
merger and acquisition in order to enhance their product portfolio.
At the same time, increasing numbers collaborations among market
players and medical research institutes are leading to new product
development.
Buy Atopic Dermatitis Treatment Market Report @
No comments:
Post a Comment